Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid is a synthetic small molecule compound with the molecular formula C25H25NO4 and a molecular weight of approximately 403.5 g/mol[1][3][5]. It is an experimental drug that has been studied as a ligand for peroxisome proliferator–activated receptor gamma (PPARγ), acting as an agonist[6]. PPARγ is a nuclear hormone receptor involved in the regulation of glucose and lipid metabolism, making this compound of interest in metabolic disease research, particularly for conditions such as type 2 diabetes and related metabolic disorders. The compound has not been approved for clinical use and there are no known marketed formulations or brand names associated with it[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid.